Drugmaker Mylan NV said on Monday it secured approval to establish its generic model of Gilead Sciences Inc’s Covid-19 therapy medication remdesivir in India this month at $4,800 per 100 mg vial, as illnesses surge on earth’s third worst-hit country by herpes. The Drug Controller General of India (DCGI) accepted Mylan’s remdesivir model, to be…